Core Insights - The ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis has a balanced demographic and disease characteristic profile, representative of the target trial population [1][4] - Real-world evidence indicates that the target market for efzofitimod is larger than previously estimated, with increased morbidity among patients [1][3] - Approximately 75% of diagnosed pulmonary sarcoidosis patients in the U.S. require treatment with steroids, highlighting the reliance on corticosteroids despite their limited clinical evidence and side effects [1][3][6] Company Overview - aTyr Pharma, Inc. is a clinical-stage biotechnology company focused on developing first-in-class medicines from its proprietary tRNA synthetase platform [2][10] - The lead therapeutic candidate, efzofitimod, is in clinical development for interstitial lung disease (ILD), specifically targeting pulmonary sarcoidosis and systemic sclerosis-related ILD [9][10] Clinical Study Details - The Phase 3 EFZO-FIT™ study has enrolled 268 patients, with 264 dosed and included in the analysis, focusing on a moderate to severe chronic symptomatic pulmonary sarcoidosis population [7][8] - The mean baseline oral corticosteroid dose among participants was 10.55 mg, with 38.3% on steroid-sparing immunosuppressants at baseline [7] Treatment Landscape - Glucocorticoids remain the most common treatment for pulmonary sarcoidosis, with higher usage rates than previously reported [6] - Treatment intensity escalates over time, with patients rapidly progressing to later-line therapies, and 10% of non-incident patients requiring high-cost, off-label biologics within three years [6] Epidemiological Insights - Approximately 158,900 individuals in the U.S. have pulmonary sarcoidosis with parenchymal involvement, with an estimated 30,000 new cases diagnosed annually [12] - The disease disproportionately affects women and Black individuals, with 1 in 8 patients hospitalized within three years, and an average hospital stay exceeding 5 days [12]

Core Insights - aTyr Pharma has advanced its investigational new drug candidate, ATYR0101, which will be presented at the ATS 2025 Respiratory Innovation Summit, highlighting its unique anti-fibrotic mechanism through interaction with LTBP-1 [2][4][5] Company Overview - aTyr Pharma is a clinical stage biotechnology company focused on developing first-in-class medicines from its proprietary tRNA synthetase platform [2][6] - The company’s lead therapeutic candidate is efzofitimod, which is in clinical development for interstitial lung disease [6] ATYR0101 Details - ATYR0101 is a fusion protein derived from the extracellular domain of aspartyl-tRNA synthetase (DARS) that induces apoptosis in myofibroblasts, which are crucial in the progression of fibrosis [3][5] - Preclinical data suggest that ATYR0101 may have the potential to reverse fibrosis, representing a significant advancement in treating pulmonary fibrosis [4][5] - The drug is currently undergoing IND-enabling studies, with an IND application anticipated to be filed in the second half of 2026 [4][5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 20-3435077 (State or other jurisdiction ...

Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology and treatment practices for pulmonary sarcoidosis to be present ...

Core Insights - aTyr Pharma is progressing with its clinical program for efzofitimod, a first-in-class biologic immunomodulator targeting pulmonary sarcoidosis, with topline data from the Phase 3 EFZO-FIT™ study expected in Q3 2025 [1][4][3] Company Updates - The first quarter of 2025 saw aTyr Pharma report a net loss of $14.88 million, compared to a loss of $15.49 million in the same period of 2024, with total revenues remaining at $0 [13] - Research and development expenses for Q1 2025 were $11.8 million, primarily for clinical trial costs related to the EFZO-FIT™ and EFZO-CONNECT™ studies [10][13] - The company appointed Dalia R. Rayes as Head of Commercial for the Global Efzofitimod Franchise, bringing over 25 years of experience in biotechnology and pharmaceutical commercial organizations [4] Clinical Trials - The Phase 3 EFZO-FIT™ study is a randomized, double-blind, placebo-controlled trial involving 268 patients across 85 centers in nine countries, focusing on steroid reduction as the primary endpoint [4][7] - The ongoing Phase 2 EFZO-CONNECT™ study aims to evaluate efzofitimod in patients with systemic sclerosis-related interstitial lung disease, with interim data expected in Q2 2025 [4][7] Financial Position - As of March 31, 2025, aTyr Pharma had cash and cash equivalents totaling $78.8 million, which is projected to fund operations for one year following the Phase 3 EFZO-FIT™ readout [10][15] - General and administrative expenses for Q1 2025 were reported at $4.0 million, slightly higher than the previous year's $3.5 million [10][13]

Core Insights - aTyr Pharma, Inc. is presenting preclinical data for ATYR2810, a monoclonal antibody targeting neuropilin-2 (NRP2), at the AACR Annual Meeting 2025, indicating progress in its clinical development [1][2] Group 1: Company Overview - aTyr Pharma is a clinical stage biotechnology company focused on developing first-in-class medicines from its proprietary tRNA synthetase platform [1][4] - The company's lead therapeutic candidate is efzofitimod, which is in clinical development for treating interstitial lung disease [4] Group 2: Research Findings - ATYR2810 has shown potential in combating drug resistance mechanisms in aggressive cancers like glioblastoma multiforme (GBM) [2][3] - Preclinical research indicates that ATYR2810 enhances anti-tumor immunity and significantly increases overall survival when used as a single agent [3] - The combination of ATYR2810 with anti-PD-1 therapies further improves survival rates and reduces tumor size in GBM models [3]

SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2025. Details of the conferences appear below: Conference: Jones Healthcare and Technology Innovation Conference Date: April 8 – 9, 2025Location: Las Vegas, ...

Core Viewpoint - aTyr Pharma has appointed Dalia R. Rayes as Head of Commercial for the Global Efzofitimod Franchise, aiming to advance the commercialization of efzofitimod, a potential first treatment for pulmonary sarcoidosis in over 70 years [1][2]. Company Overview - aTyr Pharma is a clinical stage biotechnology company focused on developing first-in-class medicines from its proprietary tRNA synthetase platform, targeting therapies for fibrosis and inflammation [4]. - The lead therapeutic candidate, efzofitimod, is in clinical development for interstitial lung disease (ILD), which includes immune-mediated disorders causing lung inflammation and fibrosis [4]. Appointment Details - Dalia R. Rayes brings over 25 years of experience in biotechnology and pharmaceuticals, having led product launches in rare diseases [1][2]. - Ms. Rayes previously served as Senior Vice President at ChemoCentryx, where she developed the commercial strategy for TAVNEOS® prior to its acquisition by Amgen [2]. - She has also held significant roles at Actelion Pharmaceuticals, contributing to the launch of products like VALCHLOR® and OPSUMIT® [2]. Compensation Package - As part of her appointment, Ms. Rayes was granted an option to purchase 225,000 shares of aTyr's common stock at an exercise price of $3.49 per share, with a vesting schedule over four years [3].

Group 1 - aTyr Pharma is preparing for its first pivotal event of the year, which is an interim readout, although it is considered the least interesting by some analysts [1] - The company is part of a broader focus on growth markets, particularly in the biotech sector, which is seen as having significant potential [1] - The investment strategy includes looking for undervalued stocks with strong scientific backgrounds, indicating a focus on fundamental analysis [1] Group 2 - The analyst has a beneficial long position in aTyr Pharma's shares, indicating confidence in the company's future performance [2] - The article expresses personal opinions and does not involve compensation from the company, suggesting an independent analysis [2] - There is no business relationship with aTyr Pharma, reinforcing the objectivity of the analysis [2]

aTyr Pharma, Inc. (NASDAQ:ATYR) Q4 2024 Earnings Conference Call March 13, 2025 5:00 PM ET Company Participants Ashlee Dunston - Senior Director of Investor Relations and Public Affairs Sanjay Shukla - President and Chief Executive Officer Leslie Nangle - Vice President of Research Jill Broadfoot - Chief Financial Officer Conference Call Participants Derek Archila - Wells Fargo & Company Yasmeen Rahimi - Piper Sandler Companies Faisal Khurshid - Leerink Partners LLC Prakhar Agrawal - Cantor Fitzgerald, L.P. ...